Replimune Group

REPLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.899 B

$20.03 -3.19%

Close of 6 Nov 2026

As of 6 Nov 2026, Replimune Group (REPL) has a market capitalization of $1.90B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$313.9M

Loss-making

Shares outstanding

94,800,404

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#33Hemab TherapeuticsCOAG$2.13B
#34Biocryst PharmaceuticalsBCRX$1.95B
#35Replimune GroupREPL$1.90B
#36Vir BiotechnologyVIR$1.89B
#37MesoblastMESO$1.83B

What if Replimune Group were worth as much as…

Open the what-if tool →

Gold $28.2T

$297,856.05

Per share 14,870× higher

Bitcoin $1.53T

$16,116.47

Per share 805× higher

Apple $5.02T

$52,908.87

Per share 2,641× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Replimune Group are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.